Overview

LeadArtis is a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market. 

Our drug candidates are derived from in-house R&D and our collaborations with reference research centers and other companies. We have several proprietary programs developing in multiple therapeutic areas, including immune-oncology, which is a high-growth area for companies and investors. LeadArtis offers an opportunity to participate in the development of cutting-edge immunomodulatory therapies against cancer.
 
By creating new medicines, we can create hope for future patients suffering from cancers for which current therapies are inadequate. 
 
Trimerbody® is a registered trademark and is covered by international patents.
 
LeadArtis news imageLeadArtis news image

Latest News

SARS-CoV-2 Spike Trimerbody could represent a therapeutic option for COVID-19.
14-10-2021

We are glad to report that in a recently published EMBO Journal...

"Tumor-targeted costimulatory trimerbodies for cancer Immunotherapy”- A brief discussion with Juan Perez Villar, CEO, LEADARTIS.
07-06-2021

...

Diario ABC España y Cadena Cope: Investigadores crean un nuevo anticuerpo antitumoral más eficaz
01-06-2021

El director de la unidad de inmunoterapia del cáncer del Instituto de Investigación del Hospital...